Targeting STAT3 signaling overcomes gefitinib resistance in non-small cell lung cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting STAT3 signaling overcomes gefitinib resistance in non-small cell lung cancer
Authors
Keywords
-
Journal
Cell Death & Disease
Volume 12, Issue 6, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-06-04
DOI
10.1038/s41419-021-03844-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- MET Alterations are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer
- (2020) Ibiayi Dagogo-Jack et al. CLINICAL CANCER RESEARCH
- Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
- (2020) Yi-Long Wu et al. Lancet Respiratory Medicine
- Overcoming acquired resistance of gefitinib in lung cancer cells without T790M by AZD9291 or Twist1 knockdown in vitro and in vivo
- (2019) Zhongwei Liu et al. ARCHIVES OF TOXICOLOGY
- Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018
- (2019) Jordi Remon et al. Journal of Thoracic Oncology
- Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer
- (2019) Annie Roys et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A mutual activation loop between the Ca2+-activated chloride channel TMEM16A and EGFR/STAT3 signaling promotes breast cancer tumorigenesis
- (2019) Hui Wang et al. CANCER LETTERS
- A ZEB1/p53 signaling axis in stromal fibroblasts promotes mammary epithelial tumours
- (2019) Rong Fu et al. Nature Communications
- LL1, a novel specific STAT3 inhibitor, displays anti‐colorectal cancer activities in vitro and in vivo
- (2019) Zhe Liu et al. BRITISH JOURNAL OF PHARMACOLOGY
- Exon-16-skipping HER2 as a novel mechanism of osimertinib-resistance in EGFR L858R/T790M-positive non-small-cell lung cancer
- (2019) Chia-Chi Hsu et al. Journal of Thoracic Oncology
- 2′-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing STAT3 signaling
- (2019) Yangyang Yue et al. CANCER LETTERS
- Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy
- (2019) Zuan-Fu Lim et al. Journal of Hematology & Oncology
- Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer
- (2018) Lydia Meder et al. CANCER RESEARCH
- JAK/STAT3-Regulated Fatty Acid β-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance
- (2018) Tianyi Wang et al. Cell Metabolism
- miR-1-3p and miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer cells through inhibition of c-Met signalling and EMT
- (2018) Demin Jiao et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Exposure of Barrett’s and esophageal adenocarcinoma cells to bile acids activates EGFR–STAT3 signaling axis via induction of APE1
- (2018) Ajaz A. Bhat et al. ONCOGENE
- Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization
- (2018) Yiu To Yeung et al. EBioMedicine
- Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
- (2018) Yen-Ting Lin et al. INTERNATIONAL JOURNAL OF CANCER
- Crosstalk of mTOR/PKM2 and STAT3/c‐Myc signaling pathways regulate the energy metabolism and acidic microenvironment of gastric cancer
- (2018) Sumeng Gao et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Inhibition of STAT3 blocks protein synthesis and tumor metastasis in osteosarcoma cells
- (2018) Dongqing Zuo et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- STAT3-blocked whole-cell hepatoma vaccine induces cellular and humoral immune response against HCC
- (2017) Qiuju Han et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4
- (2017) Hui Wang et al. Molecular Cancer
- MicroRNA-218 functions as a tumor suppressor in lung cancer by targeting IL-6/STAT3 and negatively correlates with poor prognosis
- (2017) Yan Yang et al. Molecular Cancer
- Dihydroartemisinin and gefitinib synergistically inhibit NSCLC cell growth and promote apoptosis via the Akt/mTOR/STAT3 pathway
- (2017) Hong Jin et al. Molecular Medicine Reports
- Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma
- (2017) Kuisheng Liu et al. Cell Death & Disease
- Second- and third-generation ALK inhibitors for non-small cell lung cancer
- (2016) Jingjing Wu et al. Journal of Hematology & Oncology
- STAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis in gastric cancer
- (2016) Yuan-Ming Pan et al. Molecular Cancer
- Let-7a enhances the sensitivity of hepatocellular carcinoma cells to cetuximab by regulating STAT3 expression
- (2016) Fei Xue et al. OncoTargets and Therapy
- IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis
- (2014) Matjaz Rokavec et al. JOURNAL OF CLINICAL INVESTIGATION
- ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer
- (2014) Sandra Van Schaeybroeck et al. Cell Reports
- Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
- (2013) Muhammed Murtaza et al. NATURE
- STAT3 SIGNALING: Anticancer Strategies and Challenges
- (2011) P. A. Johnston et al. MOLECULAR INTERVENTIONS
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Proteomic Signatures of Epidermal Growth Factor Receptor and Survival Signal Pathways Correspond to Gefitinib Sensitivity in Head and Neck Cancer
- (2009) F. G. Pernas et al. CLINICAL CANCER RESEARCH
- Câncer de pulmão: histologia, estádio, tratamento e sobrevida
- (2008) Fabiola Trocoli Novaes et al. Jornal Brasileiro de Pneumologia
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now